Standard BioTools to Sell Microfluidics Business to ARCHIMED
Standard BioTools has entered into a definitive agreement to divest its Microfluidics business to ARCHIMED. The transaction is anticipated to be finalized within approximately 30 days.
Standard BioTools has entered into a definitive agreement to divest its Microfluidics business to ARCHIMED. The transaction is anticipated to be finalized within approximately 30 days.